Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Brain zaps and poles: new combo therapy for Parkinson's gait

NCT ID NCT07381907

Symptom relief Sponsor: Universidade Metodista de Piracicaba Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding a mild, non-invasive brain stimulation (tDCS) to a supervised Nordic walking program improves walking speed and balance in people with Parkinson's disease. Forty participants will be randomly assigned to receive either real or fake tDCS during 12 walking sessions over four weeks. The main goal is to see if the combination helps people walk faster and feel more stable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
transcranial direct current stimulation (tDCS) device and Nordic walking program
What this could lead to
If it works, this could point toward a non-drug, low-risk way to help people with Parkinson's walk faster and feel steadier, reducing fall risk.
What could go wrong
This is a small, early-stage trial with only 40 people. The sham group also gets the walking program, so the added benefit of tDCS may be small or absent. Results may not apply to all stages of Parkinson's.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 40 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Idiopathic Parkinson's disease (e.g., UK Brain Bank criteria) * Hoehn \& Yahr stage II-IV (on medication) * Stable antiparkinsonian medication for ≥4 weeks before enrollment * Slowed gait phenotype (e.g., ≥6 seconds on 10-Meter Walk at preferred speed) * Able to ambulate at least 10 meters with or without a cane/poles (no hands-on assistance from a therapist) * Able to follow simple commands; provides written informed consent (MMSE ≥24 or equivalent cognitive screening) * Willing to maintain stable PD medication and usual care during the 4-week intervention, unless medically required Exclusion Criteria: * Contraindications to tDCS: implanted cranial/brain devices (e.g., DBS), metal in the skull (excluding dental), active skin disease/lesions at electrode sites, uncontrolled epilepsy or history of seizure in the past 12 months * Unstable medical or psychiatric conditions that preclude safe participation (e.g., uncontrolled hypertension, recent cardiovascular events, severe orthostatic hypotension with syncope) * Severe freezing of gait or fall risk that prevents safe participation in supervised Nordic Walking, as judged by the clinical team * Severe musculoskeletal or vestibular disorders that limit walking with poles; severe uncorrected visual impairment * Cognitive impairment incompatible with consent or testing (e.g., MMSE \<24) * Current participation in other interventional trials targeting gait/balance or brain stimulation; recent initiation or dose change of antiparkinsonian medication within 4 weeks.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gait disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Mobility Limitation Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gait disorders Parkinson disease (PD) Postural balance

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • UEAFTO - Unidade de Fisioterapia e Terapia Ocupacional

    RECRUITING

    Belém, Pará, 66087-670, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.